- Home
- SEVN vs ATAI Comparison
SEVN vs ATAI Comparison
Compare SEVN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- ATAI
- Stock Information
- Founded
- SEVN 1986
- ATAI 2018
- Country
- SEVN United States
- ATAI Germany
- Employees
- SEVN N/A
- ATAI N/A
- Industry
- SEVN Real Estate Investment Trusts
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- ATAI Health Care
- Exchange
- SEVN Nasdaq
- ATAI Nasdaq
- Market Cap
- SEVN 209.5M
- ATAI 218.1M
- IPO Year
- SEVN N/A
- ATAI 2021
- Fundamental
- Price
- SEVN $14.18
- ATAI $1.20
- Analyst Decision
- SEVN Strong Buy
- ATAI Strong Buy
- Analyst Count
- SEVN 3
- ATAI 3
- Target Price
- SEVN $14.50
- ATAI $10.50
- AVG Volume (30 Days)
- SEVN 71.1K
- ATAI 567.0K
- Earning Date
- SEVN 10-28-2024
- ATAI 11-12-2024
- Dividend Yield
- SEVN 9.78%
- ATAI N/A
- EPS Growth
- SEVN N/A
- ATAI N/A
- EPS
- SEVN 1.55
- ATAI N/A
- Revenue
- SEVN $33,543,000.00
- ATAI $378,000.00
- Revenue This Year
- SEVN N/A
- ATAI $44.72
- Revenue Next Year
- SEVN N/A
- ATAI N/A
- P/E Ratio
- SEVN $9.22
- ATAI N/A
- Revenue Growth
- SEVN 11.31
- ATAI 38.97
- 52 Week Low
- SEVN $10.14
- ATAI $1.03
- 52 Week High
- SEVN $14.48
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- SEVN 58.48
- ATAI 53.81
- Support Level
- SEVN $13.85
- ATAI $1.08
- Resistance Level
- SEVN $14.48
- ATAI $1.22
- Average True Range (ATR)
- SEVN 0.24
- ATAI 0.07
- MACD
- SEVN 0.03
- ATAI 0.01
- Stochastic Oscillator
- SEVN 66.29
- ATAI 85.00
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.